Risk factors

X4 Pharmaceuticals (XFOR) risk factors

Item 1A of every X4 Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next.

Open XFOR in Gloomberb →
  • FY2025 10-K risk factors

    62 risks, 13 new, 14 dropped, 14 reworded since the prior year. X4 Pharmaceuticals restructured operations, reducing headcount by 50% in September 2025 to focus on the 4WARD Phase 3 trial for mavorixafor in congenital neutropenia.

    Filed Mar 17, 2026
  • FY2024 10-K risk factors

    63 risks. X4 Pharmaceuticals faces substantial operating losses and requires additional capital to fund its commercialization and development programs.

    Filed Mar 26, 2025